SCHEMBL5028615

SCHEMBL5028615

O=C(O)C1CCN(C(c2ccccc2)C2CC2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CACNA2D1 P54289 5/20 0.50
CACNA1B Q00975 5/20 0.50
CACNB1 Q02641 5/20 0.50
CACNA1C Q13936 4/20 0.50
OPRM1 P35372 2/20 0.50
OPRD1 P41143 2/20 0.50
OPRK1 P41145 2/20 0.50
OPRL1 P41146 2/20 0.50
L3MBTL1 Q9Y468 1/20 0.45
NOTUM Q6P988 3/20 0.45
RAB9A P51151 2/20 0.44
ALDH1A1 P00352 1/20 0.44
POLB P06746 2/20 0.43
APAF1 O14727 1/20 0.43
NSD2 O96028 1/20 0.43
MAPT P10636 1/20 0.43
THRB P10828 1/20 0.43
CASP3 P42574 1/20 0.43
RECQL P46063 1/20 0.43
GALK1 P51570 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18263730 0.81 ALDH1A1 (0.64) CACNA2D1CACNA1BCACNB1CACNA1COPRM1
SCHEMBL2907024 0.79 L3MBTL1 (0.46) L3MBTL1NOTUMRAB9AALDH1A1POLB
SCHEMBL18263808 0.79 LTA4H (0.62) OPRM1OPRD1OPRK1OPRL1L3MBTL1
SCHEMBL643255 0.78 TDP1 (0.49) CACNA2D1CACNA1BCACNB1CACNA1COPRM1
SCHEMBL28554103 0.74 OPRM1 (0.57) CACNA2D1CACNA1BCACNB1CACNA1COPRM1
SCHEMBL11888863 0.74 ALDH1A1 (0.55) CACNA2D1CACNA1BCACNB1CACNA1COPRM1
SCHEMBL28468740 0.73 KMT2A (0.55) OPRM1OPRD1OPRK1OPRL1NOTUM
SCHEMBL28467466 0.73 KMT2A (0.55) OPRM1OPRD1OPRK1OPRL1NOTUM
SCHEMBL28469518 0.73 KMT2A (0.55) OPRM1OPRD1OPRK1OPRL1NOTUM
SCHEMBL28467467 0.73 KMT2A (0.55) OPRM1OPRD1OPRK1OPRL1NOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080280879-A1 SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS PFIZER INC 2008-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280879-A1 SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS XDH, CYP2D6, F12 CACNA2D1 2285/4885CACNA1B 1503/4885CACNB1 3459/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.